Sarepta Therapeutics faces class action lawsuit over securities fraud allegations.

Sarepta Therapeutics is facing a class action lawsuit alleging securities fraud and unlawful business practices. The lawsuit was filed by Pomerantz LLP and concerns the death of a young patient who participated in a clinical trial for Sarepta's gene therapy treatment. Investors who purchased or acquired Sarepta securities between March 18, 2021, and March 18, 2022, have until August 25, 2022, to ask the court to appoint them as lead plaintiff. A copy of the complaint can be obtained at www.pomerantzlaw.com.

Sarepta Therapeutics Inc. (NASDAQ: SRPT) is facing a class action lawsuit alleging securities fraud and unlawful business practices. The lawsuit was filed by Pomerantz LLP and concerns the death of a young patient who participated in a clinical trial for Sarepta's gene therapy treatment, ELEVIDYS [2]. The complaint alleges that the company made false and misleading statements about the safety profile, clinical development, and commercial prospects of ELEVIDYS [2].

The lawsuit specifically targets the period between June 22, 2023, and June 24, 2025 [1]. During this time, Sarepta disclosed several adverse events related to ELEVIDYS, including the death of two patients due to acute liver failure [1]. These disclosures led to significant declines in Sarepta's stock price, with shares dropping 27.44% on March 18, 2025, 7.13% on April 4, 2025, 42.12% on June 15, 2025, and 8.01% on June 24, 2025 [2].

Investors who purchased or acquired Sarepta securities during the relevant time frame are encouraged to contact Pomerantz LLP to learn more about the class action lawsuit and the opportunity to participate [2]. The deadline to ask the court to appoint a lead plaintiff is August 25, 2025 [1, 2].

References:

[1] https://www.globenewswire.com/news-release/2025/07/11/3114259/3080/en/Lost-Money-on-Sarepta-Therapeutics-Inc-SRPT-Join-Class-Action-Suit-Seeking-Recovery-Contact-Levi-Korsinsky.html

[2] https://www.marketscreener.com/quote/stock/SAREPTA-THERAPEUTICS-INC-11204214/news/Pomerantz-Law-Firm-Reminds-Investors-with-Losses-on-their-Investment-in-Sarepta-Therapeutics-Inc-o-50450410/